The above studies demonstrated that CIB2 acts as a negative regulator of mTORC1, and hence, we reasoned that CIB2 overexpression may partially downregulate the hyperactivated mTORC1 signaling observed in TSC and LAM. The gene discussed is CIB2; the disease is lymphangioleiomyomatosis.